SBIR/STTR Research Award

A Novel Approach to mRNA Isolation using PNAs

Award identifier 3f27f6acbe254f5f0f0290fbba8592e328677c12f14dd2c3abae955887cac7b2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$93,197

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ACTIVE MOTIF, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
N7GVF5GCF3A6
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Applicant's abstract): Peptide nucleic acids (PNAs) have a number of features that suggest they would be ideal probes for purifying mRNA. In this revised format we have demonstrated the use of phosphono PNAs (pPNAs) in an RNA isolation procedure that improves the recovery of RNAs with secondary structure at the poly A region and RNAs with short poly A tails. We have developed a procedure for isolating mRNA (free of genomic DNA) from cells and tissue using pPNAs, and provided this kit to the research community. The goal of this revised Phase I study is to further develop the pPNA technology as to enable isolation of mRNA in a high-throughput format. Also by incorporating a novel PNA-like monomer on the base of trans-4-hyroxy-L-proline (HypNA) into the pPNA backbone we hope to be able to purify mRNA from plant Total RNA. This development of PNA technology would enable the HypNA-pPNA chimera to hybridize with plant mRNA molecules regardless of the presence of plant polyphenolics. In Phase II of this study, we would hope to further develop this technology such that it can be used in a novel approach to mRNA isolation from bacterial cells as well as to develop HypNA-pPNAs chimeras for array technology. PROPOSED COMMERCIAL APPLICATION: Any group that is trying to obtain a complete set of transcripts may find an application for pPNA technology. This may include those working on the Mammalian Gene Collection (MGC). We already supply the first two versions of the kit, Maxi and Midi mVADER, to the research community. Any future products generated from this proposal will also be provided to the research community. With the 96-well format this kit will allow high throughput analysis of gene expression for drug screening and functional genomics-applications. This kit would also facilitate those interested in generating mRNA for array profiles or for those interested in studying quantitative RT-PCR. We believe that the invading properties of pPNAs will enable capture of plant mRNA molecules even in the presence of lipopolysaccharides and polyphenolics. The successful application of pPNA technology to plant biotechnology would certainly increase the market potential of this product.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

23 SBIR/STTR records share this UEI (2001–2025). Reported award amounts total $5,925,376. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.